In the Department of Translational Research & Drug Development, anti-HMGB1 monoclonal antibody, biomaterial histidine-rich glycoprotein and anti-oxidative stress-modified antigen monoclonal antibody have been studied for aiming at the clinical applications in collaboration with plural pharmaceutical companies.